Posted by Michael Wonder on 02 Apr 2020
Seqirus announces positive CHMP Opinion for its adjuvanted quadrivalent influenza vaccine
31 March 2020 - Seqirus today announced that its adjuvanted quadrivalent influenza vaccine - launching as Fluad Tetra - has received a positive opinion from the CHMP of the European Medicines Agency, recommending the approval of the marketing authorisation application for use in people aged 65 years and above.
The European Commission approval is also applicable in the UK. During the Brexit transition period the UK is still subject to EU legislation and regulatory decisions.
